Aspirin modulates ZNF24 to attenuate the NF-κB/PD-L1 axis in hepatocellular carcinoma

PD-L1-mediated immune evasion is a central obstacle to effective immunotherapy in hepatocellular carcinoma (HCC), yet the upstream transcriptional programs that sustain nuclear factor kappa-B (NF-κB)-driven PD-L1 expression remain incompletely defined. Here, we identify zinc finger protein 24 (ZNF24) as a previously uncharacterized transcriptional regulator associated with the NF-κB/PD-L1 axis in HCC and provide evidence that aspirin treatment is associated with reduced ZNF24, p65, and PD-L1 expression at multiple levels. Integrated transcriptomic profiling and molecular docking were used to identify aspirin-responsive zinc finger proteins in HCC cells. A diethylnitrosamine-induced rat model validated findings in vivo. Mechanistic studies included chromatin immunoprecipitation, dual-luciferase reporter assays, lentiviral-mediated ZNF24 overexpression in HepG2 and Hep3B cells, and Western blotting. Molecular docking predicted the highest aspirin binding affinity for the ZNF24 SCAN domain (− 8.4 kcal/mol) among candidate zinc finger proteins. Aspirin significantly reduced hepatic ZNF24, phosphorylated p65, and PD-L1 expression in vivo. Chromatin immunoprecipitation and luciferase assays were consistent with ZNF24 binding the p65 promoter and activating NF-κB signaling transcriptionally, upregulating PD-L1. ZNF24 overexpression accelerated proliferation, migration, and invasion of hepatocellular carcinoma cells while elevating p65 and PD-L1; these effects were attenuated by aspirin (up to 5 mM) or the NF-κB inhibitor SN50. A linear-regression-based computational model of downregulate ZNF24 expression in a hepatocellular carcinoma patient cohort predicted downregulation of p65 (− 9.5%) and PD-L1 (− 23.1%). Elevated ZNF24 correlated with advanced tumor stage, histological grade, and immune checkpoint markers. Aspirin suppresses the ZNF24/NF-κB/PD-L1 signaling axis in HCC, implicating ZNF24 as a candidate upstream mediator. These findings provide a translational rationale for aspirin as an adjunct to immunotherapy in HCC, subject to further mechanistic and immune-functional validation.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-11-21
DOI
https://doi.org/10.1007/s00262-026-04641-3
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Aspirin modulates ZNF24 to attenuate the NF-κB/PD-L1 axis in hepatocellular carcinoma

Chenrui Liu, Shuangsuo Dang, Yaping Li, MuQi Wang et al.
Cancer Immunology Immunotherapy
Cancer Immunotherapy and Biomarkers
article

Aspirin modulates ZNF24 to attenuate the NF-κB/PD-L1 axis in hepatocellular carcinoma

Chenrui Liu, Shuangsuo Dang, Yaping Li, MuQi Wang, Mei Li, Yang Liu, Yikai Wang, Yindi Tian, Xiaoli Jia, Meng Zhang, Juanjuan Shi, Wenjun Wang, Luna Liu
article en

Abstract

PD-L1-mediated immune evasion is a central obstacle to effective immunotherapy in hepatocellular carcinoma (HCC), yet the upstream transcriptional programs that sustain nuclear factor kappa-B (NF-κB)-driven PD-L1 expression remain incompletely defined. Here, we identify zinc finger protein 24 (ZNF24) as a previously uncharacterized transcriptional regulator associated with the NF-κB/PD-L1 axis in HCC and provide evidence that aspirin treatment is associated with reduced ZNF24, p65, and PD-L1 expression at multiple levels. Integrated transcriptomic profiling and molecular docking were used to identify aspirin-responsive zinc finger proteins in HCC cells. A diethylnitrosamine-induced rat model validated findings in vivo. Mechanistic studies included chromatin immunoprecipitation, dual-luciferase reporter assays, lentiviral-mediated ZNF24 overexpression in HepG2 and Hep3B cells, and Western blotting. Molecular docking predicted the highest aspirin binding affinity for the ZNF24 SCAN domain (− 8.4 kcal/mol) among candidate zinc finger proteins. Aspirin significantly reduced hepatic ZNF24, phosphorylated p65, and PD-L1 expression in vivo. Chromatin immunoprecipitation and luciferase assays were consistent with ZNF24 binding the p65 promoter and activating NF-κB signaling transcriptionally, upregulating PD-L1. ZNF24 overexpression accelerated proliferation, migration, and invasion of hepatocellular carcinoma cells while elevating p65 and PD-L1; these effects were attenuated by aspirin (up to 5 mM) or the NF-κB inhibitor SN50. A linear-regression-based computational model of downregulate ZNF24 expression in a hepatocellular carcinoma patient cohort predicted downregulation of p65 (− 9.5%) and PD-L1 (− 23.1%). Elevated ZNF24 correlated with advanced tumor stage, histological grade, and immune checkpoint markers. Aspirin suppresses the ZNF24/NF-κB/PD-L1 signaling axis in HCC, implicating ZNF24 as a candidate upstream mediator. These findings provide a translational rationale for aspirin as an adjunct to immunotherapy in HCC, subject to further mechanistic and immune-functional validation.

Cancer Immunology Immunotherapy
Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon